Phase I/II Study of Combination Golcadomide and Nivolumab in Patients with Non-Hodgkin Lymphoma with Refractory Disease After Chimeric Antigen T-cell Therapy
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs Golcadomide (Primary) ; Nivolumab (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 17 Jan 2025 New trial record